

REVISTA DE GASTROENTEROLOGÍA DE MÉXICO



ORIGINAL ARTICLE

# Fibrosis assessment in patients with nonalcoholic fatty liver disease: Adherence to proposed algorithms and barriers to complying with them $^{\diamond}$



S. Marciano<sup>a,b,\*</sup>, M. Dirchwolf<sup>c</sup>, M.C. Torres<sup>a</sup>, J. Allevato<sup>d</sup>, C. García Dans<sup>e</sup>, B. García<sup>f</sup>,

- F. Pollarsky<sup>g</sup>, L. Gaite<sup>h</sup>, E. Sirotinsky<sup>i</sup>, B. Rios<sup>j</sup>, M.N. Anselmo<sup>k</sup>, M. Peche<sup>l</sup>,
- E. Hurtado<sup>m</sup>, L. Haddad<sup>a</sup>, A. Narvaez<sup>a</sup>, E. Mauro<sup>a</sup>, A. Martinez<sup>n</sup>, C. Bellizzi<sup>n</sup>,
- N. Ratusnu<sup>o</sup>, C. D'Amico<sup>p</sup>, S. Arora<sup>q</sup>, A. Gadano<sup>a,b</sup>

<sup>a</sup> Sección Hepatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

- <sup>b</sup> Departamento de Investigación, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
- <sup>c</sup> Sección Hepatología, Hospital Privado de Rosario, Rosario, Argentina
- <sup>d</sup> Unidad de Diagnóstico y Tratamiento para Enfermedades Hepáticas de Neuquén, Neuquén, Argentina
- <sup>e</sup> Sección Hepatología, Hospital Zonal Bariloche Dr. Ramón Carrillo, Bariloche, Argentina
- <sup>f</sup> Sección Hepatología, Centro de Estudios Digestivos de Mendoza, Mendoza, Argentina
- <sup>g</sup> Sección Hepatología, Hospital Dr. Carlos Bonorino Udaondo, Buenos Aires, Argentina

<sup>h</sup> Sección Hepatología, Clínica de Nefrología, Santa Fe, Argentina

- <sup>i</sup> Centro de Estudios Digestivos, Comodoro Rivadavia, Argentina
- <sup>j</sup> Hepatología, Centro de Investigación, Neuquén, Argentina
- <sup>k</sup> Sección Gastroenterología y Hepatología, Hospital Zonal Esquel, Esquel, Argentina

<sup>l</sup> Hospital López Lima Gral Roca, Rio Negro, Argentina

<sup>m</sup> Hospital Municipal Coronel Suárez, Buenos Aires, Argentina

<sup>n</sup> Sección Gastroenterología, Hospital Juan A. Fernández, Buenos Aires, Argentina

° Hospital Regional de Ushuaia, Ushuaia, Tierra del Fuego, Argentina

<sup>p</sup> Hepatología, CEMA - Centro de Especialidades Médicas Ambulatoria, Mar del Plata, Argentina

<sup>q</sup> Project ECHO, School of Medicine, University of New Mexico, Albuquerque, New Mexico, United States

Received 6 June 2020; accepted 24 August 2020 Available online 21 October 2021

**KEYWORDS** Noninvasive; Steatosis;

## Abstract

Introduction and aims: Fibrosis staging in patients with nonalcoholic fatty liver disease (NAFLD) is carried out through the application of stepwise algorithms but there is little real-world data on their use. Our aim was to calculate the number of patients with NAFLD and indeterminate or

2255-534X/© 2021 Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

<sup>\*</sup> Please cite this article as: Marciano S, Dirchwolf M, Torres MC, Allevato J, García Dans C, García B, et al. Evaluación de fibrosis en pacientes con enfermedad por hígado graso no alcohólico: adherencia a los algoritmos propuestos y barreras para cumplir con ellos. Revista de Gastroenterología de México. 2022;87:4-12.

<sup>\*</sup> Corresponding author.

E-mail address: sebastian.marciano@hospitalitaliano.org.ar (S. Marciano).

NASH; Fibrosis; ECHO; NAFLD

PALABRAS CLAVE

No invasivo; Esteatosis;

EHNA;

ECHO;

HGNA

Fibrosis;

high risk for fibrosis, assessed through noninvasive scores, that consequently underwent further staging evaluation.

*Materials and methods:* A cross-sectional multicenter cohort study was conducted on patients with NAFLD evaluated by hepatologists within the time frame of June 1 and July 31, 2018. The FIB-4 and NAFLD fibrosis scores were calculated in all the patients, and if at least one of the scores suggested indeterminate or high risk for fibrosis, we believed the patient should have undergone additional fibrosis staging assessment.

*Results*: The study included 238 patients. The median time interval from NAFLD diagnosis and inclusion in the analysis was 12.2 months (IQR 3.0–36.5). A total of 128 (54%) patients had at least one noninvasive score that suggested indeterminate or high risk for fibrosis but studies to confirm the fibrosis grade (elastography, biopsy, etc.) were performed on only 72 (56%). The main barriers encountered by the physicians for applying the staging algorithms were related to health insurance coverage and imaging study costs.

*Conclusions*: A high percentage of patients with NAFLD were at indeterminate or high risk for fibrosis, according to noninvasive scores, but additional studies were carried out on only half of them, showing low adherence to current recommendations.

© 2021 Asociación Mexicana de Gastroenterología. Published by Masson Doyma México S.A. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Evaluación de fibrosis en pacientes con enfermedad por hígado graso no alcohólico: adherencia a los algoritmos propuestos y barreras para cumplir con ellos

### Resumen

*Introducción y objetivos:* La estadificación de la fibrosis en pacientes con enfermedad por hígado graso no alcohólico (EHGNA) se realiza aplicando distintos algoritmos. Sin embargo, hay pocos reportes de cómo se utilizan en la vida real. Nuestro objetivo fue estimar la proporción de pacientes con EHGNA que teniendo riesgo indeterminado o alto de fibrosis según scores no-invasivos se someten a estudios adicionales de estadificación.

*Materiales y métodos:* Estudio de corte transversal multicéntrico de pacientes con EHGNA evaluados por hepatólogos del 1 de junio del 2018 al 31 de julio del 2018. Se calcularon FIB-4 y NAFLD fibrosis score en todos los pacientes y se consideró que, si al menos uno de los scores sugería riesgo indeterminado o alto de fibrosis, el paciente debería haberse sometido a estudios adicionales de estadificación.

*Resultados:* Se incluyeron 238 pacientes. La mediana de tiempo entre el diagnóstico de EHGNA y la inclusión en el estudio fue de 12.2 (IQR 3.0-36.5) meses. En total, 128 (54%) pacientes tuvieron al menos una evaluación con score no-invasivo que sugería riesgo indeterminado o alto de fibrosis. Sin embargo, solamente 72 (56%) se realizaron estudios para confirmar el grado de fibrosis (elastografía, biopsia, etc.). Las principales barreras encontradas por los médicos para aplicar los algoritmos de estadificación fueron relacionadas a cobertura de salud y a costos.

*Conclusiones*: Un alto porcentaje de pacientes con EHGNA tiene riesgo indeterminado o alto de fibrosis, de acuerdo con los resultados obtenidos con scores no invasivos. Sin embargo, solamente la mitad se realizó estudios adicionales, evidenciando una baja adherencia a las recomendaciones actuales.

© 2021 Asociación Mexicana de Gastroenterología. Publicado por Masson Doyma México S.A. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).

# Introduction

Nonalcoholic fatty liver disease (NAFLD) is considered the most prevalent cause of liver disease worldwide<sup>1</sup>, affecting approximately 25% of the world population<sup>2</sup>. There is an abundance of data regarding the epidemiology of NAFLD in developed countries, indicating a mean prevalence of 24% in Europe and in the United States<sup>3,4</sup>. The prevalence of NAFLD in South America appears to be even higher, affecting more than 30% of the population<sup>3</sup>.

The spectrum of NAFLD ranges from nonalcoholic fatty liver, a stage with a more favorable liver-related prognosis, to nonalcoholic steatohepatitis (NASH), which is associated with progressive fibrosis and a higher risk for developing cirrhosis and hepatocellular carcinoma<sup>5</sup>. Given that NASH and its consequences will occur in only a minority of patients<sup>3,5</sup>, the identification of that population is paramount, so they can be offered proper follow-up and care.

The gold standard for the diagnosis of NASH is liver biopsy, but due to the epidemic proportions of the disease, offering an invasive procedure that entails the risk of complications and is prone to sampling errors appears impractical. Thus, several guidelines have proposed the use of noninvasive tools for fibrosis evaluation, and a stepwise algorithm has been recommended to simplify the clinical management of patients with NAFLD<sup>6</sup>. The initial steps include calculating noninvasive scores based on clinical features and serum biomarkers to classify the risk of fibrosis, and only patients with indeterminate or high risk are referred for a second assessment, with other noninvasive imaging techniques, such as elastography. Liver biopsy is offered only to patients in whom noninvasive assessment cannot exclude advanced fibrosis<sup>6</sup>.

The use of noninvasive tools is recommended and they are widely available<sup>7</sup>, but there is a well-known gap between the knowledge of guidelines and their implementation in daily practice<sup>8</sup>. Furthermore, other factors, such as barriers related to healthcare insurance coverage or local availability of technology, can impact the use of certain tools, such as elastography, in developing countries.

The adherence to recommended algorithms for fibrosis assessment in patients with NAFLD in Latin America is unknown. Thus, the primary aim of the present study was to estimate the proportion of NAFLD patients with indeterminate or high risk of fibrosis, as determined by noninvasive scores, that consequently underwent imaging studies to assess fibrosis, in real-world practice. Additionally, we sought to identify barriers to complying with the proposed fibrosis staging algorithms.

# Materials and methods

## Study design and variables

We conducted a cross-sectional multicenter study of patients with NAFLD, utilizing the Extension for Community Healthcare Outcomes (ECHO) NAFLD Clinic. Said model employs videoconferencing technology as a platform to deliver specialty medical care, by training and supporting healthcare providers so they can provide the best medical care in their local communities<sup>9</sup>.

The ECHO-NAFLD clinic was launched in February 2018 and consists of monthly 90-min teleconferences directed by an expert multidisciplinary team at the *Hospital Italiano* in Buenos Aires, Argentina. During the teleconference, participants from different regions of Argentina present patients with NAFLD to the multidisciplinary expert panel and the additional participants, who then discuss the case and give recommendations for patient care.

All physicians participating in the ECHO-NAFLD clinic were invited to take part in the present study.

From June 1 to July 31, 2018, all consecutive patients with NAFLD, above 17 years of age, that received medical care from physicians participating in the ECHO-NAFLD clinic were invited to participate in the study. Patients diagnosed with cirrhosis, based on a composite of clinical signs provided by laboratory tests, endoscopy, and radiologic imaging, were excluded from the study. Patients were also excluded if they had concomitant liver diseases, were HIV positive, or if either the NAFLD fibrosis score<sup>10</sup> or the FIB-4<sup>10,11</sup> score could not be calculated with the available data. NAFLD was defined as evidence of hepatic steatosis, through imaging modalities or histologic analyses, and the lack of secondary causes of liver fat accumulation, such as significant alcohol consumption<sup>12</sup>, long-term use of steatogenic medication, or monogenic hereditary disorders<sup>13</sup>. The selection criteria were verified using a pre-designed form, in the presence of the patients.

For each patient, the study consisted of a single visit, in which the following data were collected from medical records, complementary studies, and interrogation:

- Demographics and social determinants: age, sex, type of medical insurance (public system, private insurance, or social welfare system), educational level (primary, secondary, or post-secondary), employment status (employed vs unemployed), and place of residence in an urban or non-urban area.
- Comorbidities: dyslipidemia (patients receiving any lipidlowering treatment or that presented with any of the following situations: LDL cholesterol >160 mg/dl, HDL cholesterol <40 mg/dl, or triglycerides >200 mg/dl), arterial hypertension (patients receiving antihypertensive drugs and/or that presented with a systolic or diastolic blood pressure at examination >140 or 90 mmHg, respectively), diabetes (patients receiving oral anti-diabetic drugs and/or insulin, or that had glycated hemoglobin >6.5 g/dl or at least 2 fasting glucose levels >126 mg/dl), and a history of major cardiovascular ischemic disease or cerebrovascular disease. Body mass index (BMI) was categorized according to the World Health Organization classification: normal: 15.5-24.9; overweight: 25-29.9; class I obesity: 30-34.9; class II obesity: 35-39.9; class III obesity: 40<sup>14</sup>.
- Noninvasive scores: the FIB-4<sup>11</sup> score and NAFLD fibrosis score<sup>10</sup> were calculated in all patients. Predefined cutoff points were applied to each score, to classify patients into different categories, according to the risk of fibrosis. For the FIB-4 score, indeterminate or high risk of fibrosis was set as follows:  $\geq$ 1.3 for patients 36–64 years of age and  $\geq$ 2 for patients above 64 years of age<sup>15</sup>. Indeterminate or high risk of fibrosis was set at >–1.455 for the NAFLD fibrosis score<sup>15</sup>. The FIB-4 score was not calculated in patients under 36 years of age<sup>15</sup>, based on data precluding its use to rule in advanced fibrosis in that population, and as a result, failing to identify which of those patients should undergo further staging studies<sup>15–17</sup>.
- Outcome variable: for the purpose of the present study, and according to recommendations, we accepted the following staging algorithm: patients with at least one noninvasive score that suggested indeterminate or high risk of fibrosis should have undergone imaging studies to stage fibrosis, such as transient elastography, among others<sup>6</sup>. Therefore, the outcome variable was constructed using the number of patients that had at least one noninvasive score with indeterminate or high risk of fibrosis, as the denominator, and the number of patients that underwent at least one imaging study (imaging tech-

niques  $\pm\,\mbox{ultrasound-guided biopsy})$  to stage fibrosis, as the numerator.

The age and sex of the participating physicians were also collected, and they completed a survey assessing their perception of potential barriers to having access to imaging studies for staging fibrosis in patients with NAFLD. The survey consisted of questions regarding four potential barriers, which they ranked from "most important" to "least important", according to their opinion: a) insurance and cost-related obstacles, b) a lack of awareness about the potential consequences of NAFLD in patients and the general population, c) insufficient information in the medical community on how to apply algorithms to stage fibrosis in patients with NAFLD, and d) distance from the patient's place of residence to the closest center performing fibrosis staging studies.

The present article was structured in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines.

### Statistical analysis

The qualitative variables were presented as absolute numbers and percentages and the quantitative variables were shown as median and interquartile range (IQR: 25th percentile and 75th percentile). The Fisher's exact test or chi-square test for the categorical variables and the Mann–Whitney U test for numerical variables were employed to compare the variables between patients with indeterminate or high-risk noninvasive scores, according to whether imaging studies to stage fibrosis had been conducted. When an ordinal variable was evaluated, the chi-square for trend function was applied. Tests were two-sided and significance was accepted at a p < 0.05. STATA software (StataCorp LLC, TX; version 14.2) was used for the calculations.

## Results

During the study period, a total of 24 physicians from 12 cities in Argentina were actively participating in the ECHO-NAFLD clinic, 14 of whom accepted to participate in the study (Fig. 1). Overall, 283 patients with NAFLD were evaluated within the time frame of the study and included in the analysis (Fig. 2).

Patient characteristics and comorbidities are detailed in Table 1. The median time interval from NAFLD diagnosis to inclusion in the study was 12.2 (3.0–36.5) months. A total of 126 (53%) patients were men, and the median patient age was 56 years (47–63). All patients had at least one risk factor for NAFLD. Dyslipidemia, obesity, and diabetes were registered in 175 (73%), 134 (59%), and 73 (31%) patients, respectively. Regarding social determinants, most of the patients lived in urban areas, were employed, had at least completed primary school, and had healthcare insurance.




**Figure 1** Distribution of the Argentinian sites that participated in the study.

The research sites were: 1: Esquina, 2: Santa Fe, 3: Mendoza, 4 and 5: Ciudad de Buenos Aires, 6: Coronel Suárez, 7: Mar del Plata, 8 and 9: Neuquén, 10: General Roca, 11: Bariloche, 12: Esquel, 13: Comodoro Rivadavia, 14: Ushuaia.

### **Fibrosis staging**

The distribution of the categories of the NAFLD fibrosis score and the FIB-4 score is presented in Table 2. Of the 238 patients included in the study, 128 (54%) had at least one noninvasive score result that suggested indeterminate or high risk of fibrosis but only 72 (56%) of them underwent imaging studies for fibrosis staging. The most frequently performed studies were transitional elastography, acoustic radiation force impulse (ARFI), or shear wave elastography, carried out in 30 (42%) patients, and magnetic resonance elastography, performed in 14 (19%) patients. Liver biopsy and a combination of methods (one or more imaging techniques plus liver biopsy) were carried out to stage fibrosis in 19 (26%) and 9 (13%) patients, respectively. Taking into account all 44 patients that underwent noninvasive imaging studies to assess fibrosis (transitional elastography, acoustic ARFI, shear wave elastography, or magnetic resonance imaging), 32% presented a result that suggested F0 to F1 fibrosis, whereas 68% presented a result that suggested F2



**Figure 2** Description of the study population, within the time frame of June 1 and July 31, 2018. ECHO: Extension for Community Healthcare Outcomes; NAFLD: nonalcoholic fatty liver disease; NAFLD FS: nonalcoholic fatty liver disease fibrosis score.

to F4 fibrosis. In the 26 patients that underwent liver biopsy (either as a single approach or in combination with noninvasive imaging studies), 78% presented a METAVIR score of F0 or F1, whereas 22% had scores ranging from F2 to F4.

In the 128 patients with noninvasive score results that suggested indeterminate or high risk of fibrosis, the time interval from diagnosis of NAFLD to inclusion in the study was the only variable that was different between the patients that underwent imaging studies to stage fibrosis and those that did not (Table 3). The median time interval from NAFLD diagnosis to inclusion in the study was 24.3 months (12.2–48.7) in the patients that had a complementary study to stage fibrosis vs 3.0 months (3.0–12.2) in the patients that did not (p < 0.001).

### Physician characteristics

All participating physicians were hepatologists. Their median age was 45 years (37–59) and 9 (64%) were women. Regarding access to updated guidelines and recommendations for NAFLD assessment, 7 (50%) participants stated that they had attended an international hepatology congress or postgraduate course, within the time frame of 2016–2018.

When assessing their perception of potential barriers to having access to imaging studies for staging fibrosis, 7 (50%) physicians stated that the leading barrier was related to insurance coverage and cost of the study, 4 (29%) described a lack of awareness about the potential consequences of NAFLD in patients and the general population, and 3 (21%) asserted that it was the distance from the patient's place of residence to the closest center performing studies to stage fibrosis. None of the participating physicians stated that the main barrier was insufficient information in the medical community on how to apply algorithms to stage fibrosis in patients with NAFLD.

# Discussion

Our study has several interesting findings. First, its results showed that more than 50% of the patients with NAFLD followed by hepatologists had indeterminate or high risk of liver fibrosis, as assessed by noninvasive scores. Second, imaging studies were performed in only 50% of the patients in whom further studies to stage fibrosis were indicated by algorithms. Third, the primary barrier to staging fibrosis perceived by the hepatologists was related to imaging study cost and insurance coverage.

As stated above, NAFLD has reached epidemic proportions worldwide, and said trend appears to be rapidly escalating, concomitant with the increase in the prevalence of type 2 diabetes and obesity $^{3,18,19}$ . Given that morbidity and mortality in patients with NAFLD are associated with the development of fibrosis, the detection of patients at high risk for that outcome is crucial<sup>13,20</sup>. The recent recommendations to use noninvasive scores as the first tool for fibrosis assessment in patients with NAFLD<sup>6,17</sup> appears to be a reasonable practical approach: those scores are affordable, widely accessible, and have a high negative predictive value for ruling out advanced fibrosis<sup>21</sup>. In a recent meta-analysis, the NAFLD fibrosis score and FIB-4 score were found to be the noninvasive scores with higher diagnostic accuracy for advanced fibrosis, with an area under the receiver operating characteristic curve of approximately 0.84<sup>22</sup>.

In our study, we found that a high proportion (54%) of patients had indeterminate or high risk of fibrosis, according to noninvasive scores. That finding was higher than usually expected because our cohort was predominantly made up

Table 1	Patient characteristics collected from the ECHO-
NAFLD Cli	nic, from June 1 to July 31, 2018 (n = 238).

·	. ,
Variable	Result (n = 238)
Male sex, n (%)	126 (52.9)
Age in years, median $\pm$ IQR	56.1 (47.2-63.1)
Body mass index $^{\mathrm{a}}$ , median $\pm$ IQR	31.3 (28.3-35.1)
Body mass index category <sup>a</sup> , n (%)	
Normal	19 (8.3)
Overweight	75 (32.9)
Class I obesity	75 (32.9)
Class II obesity	41 (18.0)
Class III obesity	18 (7.9)
Diabetes, n (%)	73 (30.7)
Dyslipidemia, n (%)	175 (73.5)
Hypertension, n (%)	108 (45.4)
History of cardiovascular disease, n (%)	11 (4.6)
Residence in urban area, n (%) <sup>b</sup>	226 (95.8)
Educational level, n (%) <sup>c</sup>	
Primary	56 (24.8)
Secondary	87 (38.5)
Post-secondary or higher	83 (36.7)
Employed, n (%) <sup>d</sup>	139 (68.1)
Health insurance, n (%) <sup>e</sup>	
Public system	18 (7,7)
Social welfare system	111 (47.4)
Private insurance	105 (44.9)
Elevated transaminases, n (%) <sup>f</sup>	121 (50.8)

The categorical data are expressed as absolute numbers and percentages. The numerical data are expressed as median and interquartile range.

<sup>a</sup> Available in 228 patients.

<sup>b</sup> Available in 236 patients.

<sup>c</sup> Available in 226 patients.

<sup>d</sup> Available in 204 patients.

<sup>e</sup> Available in 234 patients.

<sup>f</sup> Defined as either ALT or AST above normal levels.

Table 2Distribution of the noninvasive score results (risk<br/>of fibrosis), collected through the ECHO-NAFLD Clinic, from<br/>June 1 to July 31, 2018.

Risk of fibrosis	NAFLD fibrosisFIB-4 scorescore (n = 145)(n = 220)	
Low risk	51 (35.2)	140 (63.6)
Indeterminate risk	61 (42.1)	55 (25.0)
High risk	33 (22.7)	25 (11.4)

Data is presented as absolute numbers and percentages. The NAFLD fibrosis score could be calculated in 145 patients and the FIB-4 score in 220 patients.

of Latin overweight patients above 50 years of age, with a high prevalence of metabolic comorbidities and altered transaminases, very likely reflecting the real need for further fibrosis assessment in those patients. In addition, all the patients included in the present analysis were referred to hepatologists, reinforcing the fact that said population could have a higher risk of fibrosis than patients receiving primary care.

It is difficult to compare our results with those of previously published studies because the prevalence of NASH in a given population varies considerably, as do the scores and cutoff points utilized in each study. For instance, in a population-based study conducted in the United Kingdom, FIB-4 score results were available in 40% of 176,114 patients with NAFLD, up to 36% of whom had an indeterminate or high risk of fibrosis<sup>22,23</sup>. In another population-based study conducted on a Hispanic community in Texas, where the prevalence of NAFLD reached 52%, there were findings consistent with indeterminate or high risk of fibrosis, using different noninvasive scores, in 17–63% of the entire cohort<sup>24</sup>. Similarly, when obese patients evaluated for bariatric surgery or patients with type 2 diabetes were assessed with those tools, indeterminate or high-risk results were observed in 60% and 61% of the study population, respectively<sup>25,26</sup>.

When obtaining an indeterminate or high risk of fibrosis with noninvasive scores, a careful interpretation of the findings is needed because the primary limitation of those tools is their inferior accuracy to rule in advanced fibrosis<sup>22</sup>. Other limitations are that concomitant hepatic and extrahepatic conditions can influence the results, their accuracy is lower in younger and older patients, and that a high proportion of patients are classified in an indeterminate zone. Thus, fibrosis assessment with imaging studies is mandatory in patients with an indeterminate or high risk of fibrosis<sup>6,15,17</sup>.

During the last few years, several algorithms and practice guidelines have been proposed by different experts to stratify patients with NAFLD: there is consensus in acknowledging that a combination of noninvasive scores and imaging techniques, such as elastography (in its different modalities), is useful for identifying patients at a higher risk of fibrosis that could benefit from a liver biopsy<sup>6,13,17,27</sup>. In a recent large prospective cohort study that used a two-step algorithm (the FIB-4 score combined with the ELF test, if deemed necessary), 5-times more cases of advanced fibrosis were detected, resulting in reduced secondary care referrals, when compared with standard care, providing strong new evidence of the benefits a stepwise approach offers patients and physicians alike<sup>28</sup>.

However, the manner in which those staging algorithms are incorporated into real-world practice is not well known. The scarce information available only refers to the utilization of fibrosis staging approaches in the primary care setting, but whether hepatologists adhere to those strategies has seldom been reported<sup>28,29</sup>. In our study, only 56% of the patients that were indicated for further fibrosis assessment and followed by a hepatologist underwent additional testing. A possible explanation for the low adherence to recommended algorithms is a lack of knowledge of them, but the access to information on the part of Argentinian hepatologists appears to be adequate, given that 50% of the physicians reported that they had attended an international hepatology congress or postgraduate course within the last 2 years, where NAFLD assessment was a "hot topic". It is also thoroughly discussed in current practice guidelines<sup>13,27,30,31</sup>. Furthermore, all participating physicians declared they were familiar with the proposed fibrosis staging algorithms and were motivated to treat patients with NAFLD, ever since their involvement with ECHO-NAFLD.

The perceived barriers to staging fibrosis were related to imaging study costs, lack of medical insurance cov-

Variable	Underwent study to stage fibrosis		р
	NO (n = 56)	YES (n = 72)	
Male sex, n (%)	28 (50)	36 (50)	0.999
Age in years, median (IQR)	57.5 (53.0-67.5)	57.0 (52.5-67.5)	0.986
Body mass index <sup>a</sup> , median (IQR)	34.1 (29.7-37.9)	32.8 (28.6-35.9)	0.405
Diabetes, n (%)	24 (42.9)	35 (48.6)	0.517
Dyslipidemia, n (%)	39 (69.6)	54 (75.0)	0.500
Hypertension, n (%)	31(55.4)	39 (54.2)	0.893
History of cardiovascular disease, n (%)	2 (3.6)	3 (4.2)	0.863
Residence in urban area, n (%) <sup>b</sup>	55 (98.2)	68 (94.4)	0.275
Educational level, n (%) <sup>c</sup>			
Primary	14 (25.4)	26 (38.8)	
Secondary	26 (47.3)	23 (34.3)	0.312
Post-secondary or higher	15 (27.3)	18 (29.9)	
Employed, n (%) <sup>d</sup>	30 (62.5)	38 (60.3)	0.815
Elevated transaminases, n (%) <sup>e</sup>	33 (58.9)	38 (52.8)	0.487
Months from NAFLD diagnosis to inclusion, median (IQR) <sup>f</sup>	3.0 (3.0-12.2)	24.3 (12.2-48.7)	<0.001

**Table 3** Comparison of characteristics of patients with indeterminate or high-risk scores, according to whether or not a complementary study for staging fibrosis was performed, collected from the ECHO-NAFLD Clinic, from June 1 to July 31, 2018 (n = 128).

The categorical data are expressed as absolute numbers and percentages. The numerical data are expressed in median and interquartile range.

<sup>a</sup> Available in 123 patients.

<sup>b</sup> Available in 128 patients.

<sup>c</sup> Available in 122 patients.

<sup>d</sup> Available in 111 patients.

<sup>f</sup> Available in 125 patients.

erage and/or the distance from the patient's place of residence to the closest available site performing elastography. Those obstacles would explain the high percentage (26%) of patients that underwent liver biopsy with no prior noninvasive imaging assessment of fibrosis, given that biopsy is a more extensively available procedure that can be carried out at any hepatology center throughout the country.

In our study, we attempted to identify patient characteristics that could be associated with having access to imaging studies for staging fibrosis. Even though we explored several clinical variables and social determinants, the only variable that was different, between patients that did or did not undergo imaging studies to stage fibrosis, was the time interval from diagnosis of NAFLD to inclusion in the study. Patients that had more follow-up visits after NAFLD diagnosis were more likely to have undergone imaging studies than patients with fewer follow-up visits. It appears that greater interaction between patients and physicians is needed for having access to further testing, such as transient elastography, which is considered a "pointof-care'' technique in other regions<sup>6</sup>. That finding could correctly challenge the use of proposed staging algorithms in Argentina, given that at least two months of follow-up with a specialist are needed to complete the initial fibrosis work-up.

Our study has several strengths. First, even though it was a cross-sectional study, the researchers had data collection training and all information was recorded in a single visit, with the participation of the patient, generating consistent data and minimizing missing information. Second, to the best of our knowledge, it is the first study to address adherence to diagnostic algorithms in patients with NAFLD that are under the care of a hepatologist.

The main limitation of our study is the fact that at the time it was designed, no widely accepted two-step algorithm was available, resulting in varying degrees of adherence, depending on the strategy of choice. However, we believe said situation only underlines the current need to standard-ize diagnostic algorithms in patients with NAFLD.

In conclusion, we found that a high percentage of patients with NAFLD followed by hepatologists had indeterminate or high risk of fibrosis, assessed by noninvasive scores. However, only half of those patients underwent further diagnostic testing to stage fibrosis. The main barrier to adhering to current algorithms that was identified appears to be related to not having access to other noninvasive tools, such as elastography, whether due to lack of insurance coverage or increased distance to the closest center performing those studies. Efforts should be made by scientific societies and the national government to resolve those barriers and properly assess patients at risk for fibrosis, using those costeffective algorithms. As was the case with other prevalent liver diseases, it is likely that the best way to overcome the current problem is through education and the implementation of multidisciplinary guidelines that strongly endorse the necessity and advantages of proper fibrosis risk stratification, in patients with NAFLD.

<sup>&</sup>lt;sup>e</sup> Defined as either ALT or AST above normal levels.

# Ethical considerations

The Institutional Review Board approved the study (protocol number 3559). All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the 1975 Declaration of Helsinki, as revised in 2008. All patients were asked for oral statements of informed consent and all patients included in the analysis were above 17 years of age. The study patients cannot be identified through the data in the article.

# Funding

No specific grants were received from public sector agencies, the business sector, or non-profit organizations in relation to this study.

# Conflict of interest

The authors declare that there is no conflict of interest.

# Acknowledgements

The authors wish to thank the *Fundación Icalma* for the methodological support received for this research, as well as Project ECHO and the Health Informatics Department of the *Hospital Italiano de Buenos Aires*, for making it possible to keep ECHO-NAFLD active.

## References

- Rinella ME. Nonalcoholic fatty liver disease: a systemic review. JAMA. 2015;313:2263-73, http://dx.doi.org/ 10.1001/jama.2015.5370.
- Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69:2672–82, http://dx.doi.org/ 10.1002/hep.30251.
- 3. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20, http://dx.doi.org/10.1038/nrgastro.2017.109.
- Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84, http://dx.doi.org/10.1002/hep.28431.
- Lindenmeyer CC, McCullough AJ. The natural history of nonalcoholic fatty liver disease—an evolving view. Clin Liver Dis. 2018;22:11–21, http://dx.doi.org/10.1016/j.cld.2017.08.003.
- Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156:1264–81.e4, http://dx.doi.org/10.1053/j.gastro.2018.12.036.
- Zhou J-H, Cai J-J, She Z-G, et al. Noninvasive evaluation of nonalcoholic fatty liver disease: current evidence and practice. World J Gastroenterol. 2019;25:1307–26, http://dx.doi.org/10.3748/wjg.v25.i11.1307.
- Chew SY, Koh MS, Loo CM, et al. Making clinical practice guidelines pragmatic: how big data and real world evidence can close the gap. Ann Acad Med Singapore. 2018;47:523–7 https://www.ncbi.nlm.nih.gov/pubmed/30636269

- Marciano S, Haddad L, Plazzotta F, et al. Implementation of the ECHO telementoring model for the treatment of patients with hepatitis C. J Med Virol. 2017;89:660–4, http://dx.doi.org/10.1002/jmv.24668.
- Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846–54, http://dx.doi.org/10.1002/hep.21496.
- 11. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317–25, http://dx.doi.org/10.1002/hep.21178.
- Ratziu V, Bellentani S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372–84, http://dx.doi.org/10.1016/j.jhep.2010.04.008.
- Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67:328–57, http://dx.doi.org/10.1002/hep.29367.
- 14. Ulijaszek SJ. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. WHO technical report series 894. Pp. 252. (World Health Organization, Geneva, 2000.) SFr 56.00, ISBN 92-4-120894-625, paperback. J Biosoc Sci. 2003;35:624–5, http://dx.doi.org/10.1017/s0021932003245508.
- 15. McPherson S, Hardy T, Dufour J-F, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced nafld fibrosis. Am J Gastroenterol. 2017;112:740–51, http://dx.doi.org/10.1038/ajg.2016.453.
- Jackson JA, Konomi JV, Mendoza MV, et al. Performance of fibrosis prediction scores in paediatric non-alcoholic fatty liver disease. J Paediatr Child Health. 2018;54:172–6, http://dx.doi.org/10.1111/jpc.13689.
- Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers. J Hepatology. 2018;68:305–15, http://dx.doi.org/10.1016/j.jhep.2017.11.013.
- Sljivic S, Gusenoff JA. The obesity epidemic and bariatric trends. Clin Plast Surg. 2019;46:1–7, http://dx.doi.org/10. 1016/j.cps.2018.08.001.
- Ruilope LM, Nunes AC, Nadruz W, et al. Obesity and hypertension in Latin America: current perspectives. Hipertens Riesgo Vasc. 2018;35:70-6, http://dx.doi.org/10. 1016/j.hipert.2017.12.004.
- 20. Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. Hepatology. 2017;65:1557–65, http://dx.doi.org/10.1002/hep.29085.
- Younossi ZM, Loomba R, Anstee QM, et al. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology. 2018;68:349–60, http://dx.doi.org/10.1002/hep.29721.
- 22. Xiao G, Zhu S, Xiao X, et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology. 2017;66:1486–501, http://dx.doi.org/10.1002/hep.29302.
- 23. Alexander M, Loomis AK, Fairburn-Beech J, et al. Real-world data reveal a diagnostic gap in nonalcoholic fatty liver disease. BMC Med. 2018;16:130, http://dx.doi.org/10.1186/s12916-018-1103-x.
- 24. Pan J-J, Fisher-Hoch SP, Chen Ch, et al. Burden of nonalcoholic fatty liver disease and advanced fibrosis in a Texas Hispanic community cohort. World J Hepatol. 2015;7:1586–94, http://dx.doi.org/10.4254/wjh.v7.i11.1586.

- 25. Simo KA, McKillop IH, McMillan MT, et al. Does a calculated ''NAFLD Fibrosis Score'' reliably negate the need for liver biopsy in patients undergoing bariatric surgery? Obes Surg. 2014;24:15–21, http://dx.doi.org/10. 1007/s11695-013-1044-6.
- 26. Armstrong MJ, Hazlehurst JM, Parker R, et al. Severe asymptomatic non-alcoholic fatty liver disease in routine diabetes care; a multi-disciplinary team approach to diagnosis and management. QJM. 2014;107:33–41, http://dx.doi.org/10.1093/qjmed/hct198.
- 27. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Obes Facts. 2016;9:65–90, http://dx.doi.org/10.1159/000443344.
- 28. Srivastava A, Gailer R, Tanwar S, et al. Prospective evaluation of a primary care referral pathway for patients with

non-alcoholic fatty liver disease. J Hepatol. 2019;71:371-8, http://dx.doi.org/10.1016/j.jhep.2019.03.033.

- 29. Rinella ME, Lominadze Z, Loomba R, et al. Practice patterns in NAFLD and NASH: real life differs from published guidelines. Therap Adv Gastroenterol. 2016;9:4–12, http://dx.doi.org/10.1177/1756283x15611581.
- Aller R, Fernández-Rodríguez C, lo Iacono O, et al. Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica. Gastroenterol Hepatol. 2018;41:328–49, http://dx.doi.org/10.1016/j.gastrohep.2017.12.003.
- 31. Shah S, Dhami-Shah H, Kamble S, et al. FIB-4 cut-off of 1.3 may be inappropriate in a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol. 2020;73:216-7, http://dx.doi.org/10. 1016/j.jhep.2019.12.025.